CAR-T Supply Chain and Logistics Guide
Specialty Cold-Chain
Clinical Trials
Key takeaways
The CAR-T supply chain is a closed loop that starts and ends with one patient: cell collection, shipment to manufacturing, release testing and return of the finished product for infusion.
FDA's 2024 CAR T cell guidance expects shipping of both the leukapheresis starting material and the final product to be controlled, and validated before licensure.
Centralized CDMO manufacturing usually relies on cryopreserved product and long-distance cryogenic shipping, while point-of-care or multisite models shorten transport but must prove comparable product at each site.
Autoimmune CAR-T programs are still investigational as of October 2026 and bring new treatment sites, scheduling patterns and, in some trials, allogeneic products into the logistics plan.
Chain of identity links every bag, label and record to the right patient, and 21 CFR 1271.290 requires a distinct identification code that supports tracking from donor to recipient and back.
The CAR-T supply chain is a patient-specific loop. For an autologous product, a patient's T cells are collected by apheresis, shipped to a manufacturing site, genetically modified and expanded, tested, and then shipped back, usually frozen, to the treatment center for infusion into the same patient. CAR-T logistics is the work of keeping that loop on schedule, at the right temperature and tied to the right person at every step. A late or mislabeled shipment cannot be replaced from inventory, because there is no inventory.
This guide explains how CAR-T cell therapy shipping works, how centralized and point-of-care manufacturing change the transport plan, what the move into autoimmune disease means for logistics, and how chain of identity is maintained. Regulatory points reflect FDA and eCFR sources checked in October 2026. Confirm product-specific requirements with the sponsor or manufacturer and its regulatory team.
What is the CAR-T supply chain?
The CAR-T supply chain is the sequence of collection, transport, manufacturing, release and return that turns a patient's own cells into a treatment and brings it back to that patient. It is often called vein to vein because it starts with a blood draw and ends with an infusion. For approved products the loop typically involves at least three parties: the treatment center that collects and later infuses the cells, the manufacturer or contract manufacturer, and the logistics provider that moves material between them.
As of October 2026, FDA's list of approved cellular and gene therapy products includes seven CAR-T products: Abecma, Aucatzyl, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. All of them treat blood cancers. Their supply chains are the model that newer programs, including autoimmune ones, are building from.
The table below shows the main legs of the loop and what each one depends on.
Step | What moves | Typical condition | Main logistics risk |
|---|---|---|---|
Apheresis and pickup | Leukapheresis starting material | Fresh and temperature controlled, or cryopreserved at the collection site, as the protocol specifies | Pickup time slipping past the window the manufacturer validated |
Inbound to manufacturing | Starting material plus collection records | As validated for the starting material | Missed manufacturing slot, incomplete paperwork at receipt |
Manufacturing and release | Samples for quality control testing | Inside the facility | Release delays that push the outbound shipment |
Outbound to treatment center | Final CAR-T product | Usually cryopreserved in a liquid nitrogen dry vapor shipper below -150°C | Temperature excursion, customs hold on international lanes, closed receiving site |
Receipt and infusion | Product into site storage, then thaw | Site cryogenic storage until the infusion date | Identity mismatch, missing receipt records, no trained receiver |
CAR-T supply chain management means planning these legs as one timeline rather than as separate shipments. The apheresis date drives the manufacturing slot, the slot drives the release date, and the release date drives the outbound booking and the patient's admission.
How are CAR-T cells shipped?
CAR-T cells are shipped in two directions under different conditions. The starting material travels from the collection site to the manufacturer under conditions the sponsor has validated, and the finished product usually returns cryopreserved in a dry vapor liquid nitrogen shipper that holds it below -150°C, with continuous temperature monitoring and documented handoffs. Fresh, non-frozen products exist too, but they require much tighter timing.
FDA's final guidance, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products (January 2024), sets out the logic. It notes that fresh CAR T cells have a limited shelf life, so the maximum time between formulation and infusion should be defined and supported by stability studies. It generally recommends cryopreservation when cells are made at a central site and shipped to clinics, because freezing allows full release testing and more flexible patient scheduling. It also expects procedures that control the product during shipping, receipt, storage and preparation for infusion to be validated before licensure, and expects the shipping of leukapheresis material to the manufacturer to be controlled, for example for temperature, with information on containers and monitoring.
In practice, cryogenic shipping cell therapy lanes have a few common features.
A qualified shipper and a charged duration. The shipper is charged with liquid nitrogen that is absorbed so there is no free liquid, and its hold time sets the outer limit for the whole journey, including any delay. Our guide to transporting goods with cryogenic dewars and LN2 covers how these shippers work.
Temperature and location data. A logger records the internal temperature for the full trip, and a GPS tracker shows where the shipper is. The data file becomes part of the batch or receipt record.
Orientation and handling rules. Shippers are kept upright and closed in transit as the shipper manufacturer and the sponsor instruct, and every handoff is signed and timed.
Validated packaging. The shipping system is qualified for the lane and the worst-case conditions. For how sponsors approach this, see our article on gene therapy shipping and packaging validation.
Customs planning for international lanes. Human-derived material may need permits and pre-cleared documentation so that it does not sit in a warehouse while the shipper's hold time runs down.
Part 1271 of FDA's regulations also touches shipping. Under 21 CFR 1271, cell products regulated as biological products must follow the current good tissue practice provisions in subpart D. Section 1271.265 requires that packaging and shipping containers protect the product from contamination and that appropriate shipping conditions be established for each type of product. It also requires incoming material to be evaluated at receipt and accepted, rejected or quarantined against pre-set criteria. Autologous cells are excepted from the donor-eligibility determination in section 1271.90, which is one reason autologous CAR-T paperwork differs from that for donor-derived products.
What is the difference between point-of-care and CDMO CAR-T manufacturing?
Point-of-care CAR-T manufacturing makes the product at or near the hospital that treats the patient, while CDMO or centralized manufacturing makes it at one or a few large facilities and ships it back to many treatment centers. The point of care vs CDMO CAR-T choice is largely a trade-off between transport distance and product consistency.
FDA's 2024 guidance describes the two ends of this range. Single-site manufacturing at a centralized location may reduce product variability between facilities, but it creates logistical concerns with cryopreservation and shipping of the starting material, the final cells and the test samples. Multisite manufacturing may shorten the time from collection to administration, but differences between facilities can add variability, so the sponsor must show that a comparable product is made at each location.
Factor | Centralized or CDMO model | Point-of-care or multisite model |
|---|---|---|
Transport distance | Long, often by air and sometimes international | Short or none for the main product legs |
Usual product state | Cryopreserved for shipping and release testing | Fresh products become more practical |
Main logistics task | Cryogenic lanes, slot booking, customs, hold-time management | Local courier runs for samples, reagents and supplies, tight same-day timing |
Regulatory burden | Validate each shipping lane and container | Show comparable product and methods at every site |
Failure mode | Delay or excursion on a long route | Site-to-site variability, local staffing gaps |
Neither model removes logistics. Point-of-care programs still move test samples to reference labs, receive vector and reagents, and may ship product between sites in a network. Each manufacturing location in a multisite program needs its own qualified routes, because origins, carriers and transit times differ.
How does autoimmune CAR-T change logistics?
Autoimmune CAR-T changes logistics mainly by changing who is treated, where and on what schedule. As of October 2026, no CAR-T product for an autoimmune disease appears on FDA's approved list, so these programs run as clinical trials. A search of ClinicalTrials.gov for lupus and CAR-T in October 2026 returned dozens of recruiting studies, and similar searches cover conditions such as myasthenia gravis. That makes CAR T cell clinical logistics, rather than commercial distribution, the current reality for this field.
Several changes follow for the shipping plan.
New types of treatment sites. Trials may run through rheumatology, nephrology or neurology programs inside academic centers rather than only through established cell therapy units. Some of these teams may have less experience receiving cryogenic shippers, so site readiness checks, receiving procedures and training need to happen before the first patient.
Different scheduling pressure. Patients with autoimmune disease may be scheduled more electively than patients with relapsed cancer. That can allow more planning, but it also means appointments are less likely to move around a late shipment, so the logistics plan should protect the date.
Allogeneic products in some trials. Several autoimmune studies listed on ClinicalTrials.gov test donor-derived or cell-line-derived products rather than the patient's own cells. Those products can be made in batches and stored, which shifts logistics from a vein-to-vein loop toward inventory, depot storage and distribution to sites on demand.
Long-term follow-up. FDA continues to require manufacturers of approved CAR-T products to run postmarketing safety studies with 15 years of patient follow-up. Trial protocols for autoimmune programs also include follow-up visits, which can mean recurring sample shipments to central labs long after the infusion.
The regulatory backdrop for treatment sites has also shifted. In June 2025 FDA eliminated the REMS for approved BCMA- and CD19-directed autologous CAR T cell products, removing the requirement that dispensing hospitals be specially certified under the REMS and keep tocilizumab immediately available on site. Product labeling, with its boxed warning, still carries the safety information, and adverse event reporting continues. For logistics, this may widen the range of centers that dispense approved CAR-T over time, which adds receiving sites and lanes. Any autoimmune product approved in future will come with its own labeling and conditions, so check the label rather than assuming the oncology rules carry over.
Accreditation also shapes site readiness. The Foundation for the Accreditation of Cellular Therapy publishes FACT standards, including standards for immune effector cells, that many treatment programs use for collection, processing and administration. Whether a new autoimmune site holds that accreditation is a useful question when planning receipt and storage.
What is chain of identity in cell therapy?
Chain of identity in cell therapy is the unbroken link between a specific patient and every bag, sample, label and record made from that patient's cells, from collection through manufacturing to infusion. It answers one question at each step: is this material from the right person? Chain of custody is related but different. It records who held the material, when and under what conditions.
FDA's tracking rule for cell and tissue products gives the regulatory anchor. Under 21 CFR 1271.290, an establishment that handles the product must track it from the donor to the consignee or final disposition and back again. Each product must be assigned and labeled with a distinct identification code that relates it to the donor and to all its records, and that code must be created for tracking and may not include personal identifiers such as the patient's name or social security number.
For chain of identity cell therapy logistics, that translates into a few working rules:
Verify the patient identifier and the product code against the order at every handoff, not only at the manufacturer.
Keep labels on the shipper, the cassette and the paperwork consistent, and never relabel in transit.
Record each transfer with time, location, person and shipper temperature so the custody record and the identity record line up.
Use the sponsor's orchestration or scheduling system as the single source of truth, and reconcile courier records to it after delivery.
Treat any mismatch as a stop. The product waits until the manufacturer's quality team resolves it.
Our article on the role of chain of custody in life science shipping explains how custody records are built and audited.
Common mistakes in CAR-T logistics
The most frequent problems are planning problems. Teams reuse an oncology routing plan for a new site without checking its receiving hours. They book the outbound shipper before release is confirmed and lose hold time waiting. They treat the international return leg as routine and discover a permit gap at the border. Or they rely on one courier route with no fallback when weather or a flight cancellation hits. Each of these is avoidable with a written lane plan, a named contact at each site and an agreed backup option, such as a next flight out booking when the planned routing fails.
Mercury supports CAR-T cell therapy shipping with cryogenic dewar shippers that maintain -150°C or lower, temperature monitoring devices and GPS trackers, chain-of-custody documentation and round-the-clock monitoring, and works with partner cryogenic storage facilities. For trial programs, our clinical trial logistics team can help plan collection, manufacturing and site lanes as one schedule.
